PAMS
CLDX icon

Pictet Asset Management (Switzerland)’s Celldex Therapeutics CLDX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$60.9M Buy
1,794,048
+1,014,420
+130% +$34.2M 0.07% 262
2023
Q1 		$28.1M Buy
+779,628
New +$33.6M 0.04% 388

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CLDX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Celldex Therapeutics (CLDX) stake by 130% in Q2 2023, buying an estimated $34.2M and bringing the position to 1,794,048 shares worth $60.9M. The position accounts for 0.07% of the portfolio, ranked #262.

Pictet Asset Management (Switzerland) first reported a position in CLDX in Q1 2023 and has held it in 2 quarters since. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 1,794,048 shares of Celldex Therapeutics worth $60.9M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 1,014,420 Celldex Therapeutics shares in Q2 2023, an estimated $34.2M.
  • Celldex Therapeutics made up 0.07% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #262 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Celldex Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.